Applied DNA Sciences Announces Special Meeting of Stockholders on April 15, 2024

TL;DR

<b>Applied DNA Sciences will hold a virtual Special Meeting of Stockholders on April 15, 2024, to vote on warrant issuances and repricing.</b>

AI Summary

APPLIED DNA SCIENCES INC (BNBX) filed a Proxy Statement (DEF 14A) with the SEC on March 14, 2024. Special Meeting of Stockholders for Applied DNA Sciences, Inc. (APDN) to be held virtually on April 15, 2024, at 10:00 a.m. ET. The meeting will be conducted via live webcast, allowing stockholders to attend and submit questions online. Key agenda items include approving the issuance of common stock purchase warrants in connection with a private placement. Another agenda item is the approval of the repricing of certain warrants. The company aims to increase stockholder access, improve communication, and achieve cost savings through the virtual format.

Why It Matters

For investors and stakeholders tracking APPLIED DNA SCIENCES INC, this filing contains several important signals. The virtual format aims to enhance stockholder participation and reduce costs for the company. Approval of warrant issuances and repricing is crucial for the company's financing and strategic flexibility.

Risk Assessment

Risk Level: low — APPLIED DNA SCIENCES INC shows low risk based on this filing. The filing is a routine proxy statement for a special meeting and does not contain new financial performance data or significant operational updates.

Analyst Insight

Stockholders should review the proxy materials to understand the proposals regarding warrant issuances and repricing before the April 15, 2024 meeting.

Key Numbers

• April 15, 2024 — Special Meeting Date (Date of the Special Meeting of Stockholders)
• 10:00 a.m. Eastern Time — Meeting Time (Time of the Special Meeting)
• 0000744452 — Central Index Key (Company's SEC identifier)
• 001-36745 — SEC File Number (Company's SEC filing number)

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant name
• APDN (company) — Ticker symbol
• April 15, 2024 (date) — Date of Special Meeting
• Nasdaq Listing Rule 5635(d) (regulatory) — Rule cited for warrant issuance approval
• PROHEALTH MEDICAL TECHNOLOGIES INC (company) — Former company name
• DCC ACQUISITION CORP (company) — Former company name
• DATALINK CAPITAL CORP/TX/ (company) — Former company name

FAQ

Industry Context

Applied DNA Sciences operates in the biotechnology and life sciences sector, focusing on DNA-based technologies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

1. Review the proxy statement for details on the proposed warrant issuances and repricing.
2. Vote on the proposals at the virtual Special Meeting on April 15, 2024.
3. Ensure your contact information is up-to-date with the company for meeting access.

Key Dates

• 2024-04-15: Special Meeting of Stockholders — To approve warrant issuances and repricing.

Year-Over-Year Comparison

This is a proxy statement (DEF 14A) for a special meeting, not an annual report or quarterly filing, so direct comparison of financial metrics is not applicable.

Key Financial Figures

• $0.001 — ck split of our common stock, par value $0.001 per share (" Common Stock "), at a rati

Filing Documents

• tm247721-2_def14a.htm (DEF 14A) — 505KB
• lg_applieddna-4c.jpg (GRAPHIC) — 11KB
• px_24specialmeeting01-bw.jpg (GRAPHIC) — 244KB
• px_24specialmeeting02-bw.jpg (GRAPHIC) — 243KB
• 0001104659-24-034530.txt (&nbsp;) — 1136KB

From the Filing

DEF 14A 1 tm247721-2_def14a.htm DEF 14A tm247721-2_def14a - none - 4.7968973s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Applied DNA Sciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS APPLIED DNA SCIENCES, INC. 50 HEALTH SCIENCES DRIVE STONY BROOK, NEW YORK 11790 (631) 240-8800 March 14, 2024 Dear Fellow Stockholder: You are cordially invited to attend a Special Meeting of Stockholders (the " Special Meeting ") of Applied DNA Sciences, Inc. (" Applied DNA Sciences ," the " Company ," " we " or " us ") to be held at 10:00 a.m., Eastern Time , on Monday, April 15, 2024 . We are very pleased that the Special Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. The Special Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. You will be able to attend the Special Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/APDN2024SM. You will also be able to vote your shares electronically at the annual meeting. We are pleased to use the latest technology to increase access, to improve communication and to obtain cost savings for our stockholders and the Company. Use of a virtual meeting will enable increased stockholder attendance and participation as stockholders can participate from any location. At the meeting, you will be asked to (i) approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance to certain holders of common stock purchase warrants in connection with a private placement; (ii) approve, in accordance with Nasdaq Listing Rule 5635(d), the repricing of certain of our common stock purchase warrants; (iii) grant the Board of Directors the discretionary authority to amend the Company's certificate of incorporation, as amended, to effect a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company's Board of Directors following the Special Meeting; and (iv) approve an amendment to the Company's 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 4,000,000 shares. Detailed information with respect to these matters is set forth in the accompanying Proxy Statement, which we encourage you to carefully read in its entirety. We look forward to greeting personally those stockholders who are able to attend the meeting online. However, whether or not you plan to join us at the meeting, it is important that your shares be represented. Stockholders of record at the close of business on March 4, 2024 are entitled to notice of and to vote at the meeting. Such stockholders are urged to promptly submit the enclosed proxy card, even if their shares were sold after the record date. You may vote over the Internet, as well as by telephone or by mail pursuant to instructions provided on the proxy card. Please review the instructions for each of your voting options described in the Proxy Statement. Thank you for your ongoing support of Applied DNA Sciences. Very truly yours, /s/ James A. Hayward James A. Hayward Chairman, President and Chief Executive Officer TABLE OF CONTENTS APPLIED DNA SCIENCES, INC. NOTICE OF SPECIAL MEETING OF STOCKHOLDERS Notice is hereby given that a Special Meeting of Stockholders (the " Special Meeting ") of Applied DNA Sciences, Inc. (" Applied DNA Sciences " or the " Company "), will be held virtually at www.virtualshareholdermeeting.com/APDN2024SM on Monday, April 15, 2024 at 10:00 a.m., Eastern Time, for the following purposes: to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance to certain holders of common stock purchase warrants in connection with a private placement (the " Warrant Issuance Proposal "); to approve, in accordance with Nasdaq Listing Rule 5635(d), the repricing of certain of our common stock purchase warrants (the " Warrant Repricing Proposal "); to grant the Board of Directors discretionary authority to amend the Company's certificate of incorporation, as amended (the " Certificate of I

View Full Filing

View this DEF 14A filing on SEC EDGAR